AMR partnershipAMR: Partnership set to improve in vivo an...The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testin … more ➔
financingVectorY Therapeutics raises €129m in Ser...Dutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies. more ➔
financingViaNautis Bio Ltd closes US$25m Series A f...Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut. more ➔
Recordbreaking BIO-Europe in Munich, but:...The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already the largest European … more ➔
Amyl Therapeutics bags €11m Series A ext...Belgian amyloid fibrils specialist Amyl Therapeutics SA has got a €11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform. more ➔
Evotech screens cancer candidates for Dewp...German Evotec SE and Boston-based Dewpoint Therapeutics Inc have entered into a strategic partnership in oncology. more ➔
Pierre Fabre SA licences immunotherapy fro...Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond. more ➔
Scotland boosts bio-based manufacturing wi...Biotech companies in Scotland’s thriving bio-based manufacturing have been invited to apply for up to £1m funding within the Launchpad programme. more ➔
Memo Therapeutics AG raises CHF25mSwiss Memo Therapeutics AG will use CHF25m raised in a new Series C financing to complete a Phase II study with Anti-BKV for prevention of virus-induced graft damage. more ➔
microRNA could offer a safe target in athe...Researchers led by Wolfgang Enard from LMU Munich have identified a microRNA-based mechanism that drives atherosclerosis by weakening the integrity of blood vessel walls. more ➔
